SIGHT SCIENCES, INC. Financials Sight Sciences, Inc.
Equities
SGHT
US82657M1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.56 USD | +0.61% |
|
+17.77% | +27.13% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 831.2 | 587.9 | 251.5 | 326.4 | - | - |
| Enterprise Value (EV) 1 | 603.2 | 436.2 | 147.3 | 252.7 | 277.7 | 282.5 |
| P/E ratio | -7.44 x | -6.78 x | -4.53 x | -6.46 x | -7.23 x | -11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 17 x | 8.24 x | 3.1 x | 3.9 x | 3.47 x | 3.02 x |
| EV / Revenue | 12.3 x | 6.12 x | 1.82 x | 3.02 x | 2.95 x | 2.62 x |
| EV / EBITDA | -11.9 x | -5.24 x | -2.6 x | -6.05 x | -9.37 x | -13.7 x |
| EV / FCF | - | -5,670,246 x | - | - | - | - |
| FCF Yield | - | -0% | - | - | - | - |
| Price to Book | 3.59 x | 3.68 x | 2.11 x | 4.37 x | 6.31 x | 7.13 x |
| Nbr of stocks (in thousands) | 47,307 | 48,151 | 48,750 | 49,756 | - | - |
| Reference price 2 | 17.57 | 12.21 | 5.160 | 6.560 | 6.560 | 6.560 |
| Announcement Date | 3/24/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 48.96 | 71.33 | 81.06 | 83.59 | 94.01 | 108 |
| EBITDA 1 | - | -50.85 | -83.24 | -56.63 | -41.77 | -29.63 | -20.65 |
| EBIT 1 | - | -51.48 | -83.95 | -57.27 | -48.11 | -40.97 | -24.3 |
| Operating Margin | - | -105.15% | -117.7% | -70.66% | -57.56% | -43.58% | -22.49% |
| Earnings before Tax (EBT) 1 | - | -62.77 | -86.2 | -55.44 | -48.34 | -40.26 | -31.97 |
| Net income 1 | -34.69 | -62.96 | -86.24 | -55.55 | -48.35 | -40.27 | -31.97 |
| Net margin | - | -128.61% | -120.9% | -68.53% | -57.85% | -42.84% | -29.6% |
| EPS 2 | -3.705 | -2.360 | -1.800 | -1.140 | -1.015 | -0.9072 | -0.5942 |
| Free Cash Flow | - | - | -76.94 | - | - | - | - |
| FCF margin | - | - | -107.86% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 5/24/21 | 3/24/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.68 | 14.88 | 17.23 | 18.68 | 20.54 | 18.82 | 23.47 | 20.01 | 18.75 | 19.26 | 21.25 | 20.93 | 22.06 | 21.61 | 25.82 |
| EBITDA 1 | - | - | - | -21.66 | -16.9 | -17.42 | -15.04 | -13.25 | -10.92 | -14.53 | -14.7 | -3.8 | -3.9 | - | - |
| EBIT 1 | -14.72 | -22.19 | -22.86 | -21.84 | -17.05 | -17.57 | -15.19 | -13.41 | -11.11 | -14.72 | -13.82 | -8.964 | -7.836 | -9.926 | -13.2 |
| Operating Margin | -100.21% | -149.14% | -132.71% | -116.96% | -83.01% | -93.33% | -64.71% | -67.02% | -59.25% | -76.42% | -65.04% | -42.82% | -35.53% | -45.92% | -51.12% |
| Earnings before Tax (EBT) 1 | -15.84 | -23.25 | -23.83 | -22.21 | -16.9 | -17.05 | -14.75 | -12.96 | -10.68 | -16.25 | -14.28 | -9.428 | -8.375 | -10.75 | -14.26 |
| Net income 1 | -15.94 | -23.26 | -23.84 | -22.23 | -16.91 | -17.07 | -14.75 | -13.04 | -10.69 | -16.27 | -14.29 | -9.431 | -8.378 | -13.76 | -14.26 |
| Net margin | -108.52% | -156.33% | -138.39% | -119.02% | -82.3% | -90.67% | -62.86% | -65.15% | -57.02% | -84.43% | -67.23% | -45.05% | -37.98% | -63.67% | -55.21% |
| EPS 2 | -0.3400 | -0.4900 | -0.5000 | -0.4600 | -0.3500 | -0.3500 | -0.3000 | -0.2700 | -0.2200 | -0.3300 | -0.2871 | -0.2094 | -0.2011 | -0.2667 | -0.2667 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/24/22 | 5/10/22 | 8/11/22 | 11/10/22 | 3/13/23 | 5/4/23 | 8/3/23 | 11/7/23 | 3/7/24 | 5/2/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 228 | 152 | 104 | 73.7 | 48.7 | 43.9 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -76.9 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -87.9% | -44% | -39.6% | -48.1% | -41.6% | -35.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 4.890 | 3.310 | 2.450 | 1.500 | 1.040 | 0.9200 |
| Cash Flow per Share | - | - | -1.590 | - | - | - | - |
| Capex | - | 0.81 | 0.97 | - | - | - | - |
| Capex / Sales | - | 1.66% | 1.36% | - | - | - | - |
| Announcement Date | 5/24/21 | 3/24/22 | 3/13/23 | 3/7/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
6.56
USD
Average target price
6.1
USD
Spread / Average Target
-7.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.13% | 324M | |
| -7.16% | 177B | |
| -4.86% | 65.54B | |
| -4.28% | 47.09B | |
| +10.32% | 43.43B | |
| +8.14% | 41.77B | |
| +15.76% | 29.55B | |
| +15.53% | 24.83B | |
| -5.88% | 23.97B | |
| -5.38% | 23.54B |
- Stock Market
- Equities
- SGHT Stock
- Financials Sight Sciences, Inc.
